FDA Approves Cellceutix Corp. (CTIX) Proposed Phase I Clinical Trial for Anti-Cancer Compound
Biopharm company Cellceutix today said the U.S. Food and Drug Administration (FDA) has reviewed the company's Investigational New Drug (IND) application for its novel anti-cancer compound Kevetrin™ and has approved the company’s advancement to phase I clinical trial. The phase 1 clinical trial for Kevetrin will take place at Harvard Cancer Center's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center. The company also announced that both the Institutional Review Board and the Scientific Review Committee have approved the protocol for the clinical trial. Cellceutix said it will provide details on the commencement of the clinical trials to shareholders…